Benin 2014 | Kinshasa, DRC 2015 | Katanga, DRC 2015 | Nigeria 2015 | Kenya 2014 | Tanzania 2014 | Uganda 2015 | Zambia 2014 | |
---|---|---|---|---|---|---|---|---|
% (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | |
N = 6436 | N = 6999 | N = 1877 | N = 7077 | N = 3083 | N = 2255 | N = 7179 | N = 555 | |
Active ingredients (type) | ||||||||
Artemether lumefantrine | 64.9 (61.6, 68.1) | 67.0 (64.8, 69.2) | 75.1 (68.0, 81.1) | 65.8 (62.4, 69.0) | 40.3 (36.5, 44.2) | 29.0 (24.7, 33.7) | 52.5 (48.5, 56.4) | 75.4 (66.4, 82.6) |
Artesunate amodiaquine | 1.4 (1.0, 2.1) | 3.8 (3.1, 4.6) | 3.7 (2.9, 4.9) | 5.5 (3.7, 8.1) | 0.3 (0.2, 0.5) | 0.2 (0.1, 0.3) | 0.3 (0.1, 1.0) | 1.1 (0.2, 7.5) |
Artesunate mefloquine | 5.5 (4.3, 7.1) | 0.5 (2.6, 0.8) | <0.1 (<0.1, 0.2) | 1.4 (0.7, 2.8) | 2.8 (2.2, 3.6) | 8.2 (5.7, 11.5) | 1.1 (0.8, 1.7) | 0.0 (–) |
Artemisinin piperaquine | 0.2 (0.0, 0.8) | 1.4 (0.9, 2.1) | 1.5 (0.6, 3.5) | 0.8 (0.4, 1.6) | 8.5 (7.9, 9.3) | 19.3 (16.5, 22.4) | 0.0 (–) | 0.0 (–) |
Artemisinin naphthoquine | 1.1 (0.7, 1.5) | 0.0 (–) | 0.0 (–) | 0.0 (–) | 2.3 (1.9, 2.7) | 1.7 (0.6, 4.6) | 6.7 (5.4, 8.3) | 0.7 (0.3, 1.5) |
Artesunate SP | 8.6 (7.6, 9.7) | 9.7 (8.6, 10.8) | 7.3 (4.0, 13.0) | 1.6 (1.1, 2.4) | 3.3 (2.6, 4.1) | 0.0 (–) | 0.0 (–) | 21.2 (14.1, 30.5) |
Dihydroartemisinin piperaquine | 11.7 (9.2, 14.6) | 14.6 (13.4, 15.8) | 5.1 (3.8, 6.8) | 24.7 (22.7, 46.7) | 42.2 (40.0, 44.9) | 41.7 (37.9, 45.7) | 39.1 (36.0, 42.2) | 1.6 (14.1, 30.5) |
Dihydroartemisinin piperaquine trimethoprim | 3.4 (2.9, 3.9) | 0.2 (0.1, 0.5) | 0.0 (–) | 0.1 (<0.1, 0.2) | 0.0 (–) | 0.0 (–) | 0.0 (–) | 0.0 (–) |
Dihydroartemisinin SP | 3.3 (2.6,4.3) | 2.9 (2.5, 3.3) | 7.2 (6.3, 8.2) | 0.0 (–) | 0.0 (–) | 0.0 (–) | 0.0 (–) | 0.0 (–) |
Arterolane piperaquine | 0.0 (–) | 0.0 (–) | 0.0 (–) | 0.2 (0.1, 0.4) | 0.0 (–) | 0.0 (–) | 0.3 (0.1, 0.5) | 0.0 (–) |
Product formulation | ||||||||
Tablet | 71.2 (68.3, 74.0) | 60.2 (57.5, 62.8) | 66.1 (63.9, 68.1) | 60.8 (57.3, 64.2) | 68.5 (66.2, 70.7) | 86.4 (82.9, 89.2) | 74.7 (71.3, 77.9) | 74.3 (67.5, 80.1) |
Suspension | 25.3 (23.8, 26.9) | 39.8 (37.2, 42.5) | 33.9 (31.8, 36.1) | 35.8 (31.9, 39.9) | 30.4 (28.1, 32.9) | 13.6 (10.8, 17.0) | 25.2 (22.0, 28.6) | 25.7 (19.9, 32.5) |
Granule or suppository | 3.5 (1.5, 7.9) | <0.1 (<0.1, 0.2) | <0.1 (<0.1, 0.2) | 3.4 (2.6, 4.5) | 1.1 (0.8, 1.6) | 0.1 (<0.1, 0.2) | 0.1 (0.1, 0.3) | 0.0 (–) |
N = 6426 | N = 6986 | N = 1853 | N = 7074 | N = 3072 | N = 2237 | N = 7137 | N = 546 | |
---|---|---|---|---|---|---|---|---|
Country of manufacturea | ||||||||
Local | 0.0 (–) | 24.8 (23.4, 26.2) | 29.2 (26.9, 31.5) | 15.2 (13.1, 17.6) | 3.9 (3.3, 4.7) | 9.2 (6.7, 12.6) | 1.3 (0.9, 1.9) | 0.0 (–) |
India | 55.1 (53.1, 57.0) | 60.5 (58.2, 62.8) | 59.1 (51.7, 66.2) | 59.3 (54.1, 64.4) | 53.0 (51.3, 54.7) | 6.5 (4.7, 8.9) | 72.4 (69.3, 75.2) | 67.9 (53.1, 79.8) |
China | 18.4 (17.3, 19.6) | 2.5 (1.8, 3.4) | 2.6 (1.5, 4.3) | 21.3 (18.0, 25.1) | 27.0 (25.2, 28.8) | 62.0 (56.9, 66.8) | 23.1 (20.5, 25.9) | 4.3 (1.8, 9.7) |
European Country | 19.5 (17.8, 21.3) | 7.6 (6.7, 8.7) | 8.3 (3.7, 17.5) | 2.2 (1.0, 4.8) | 14.3 (13.0, 15.7) | 22.1 (18.5, 26.3) | 3.2 (2.3, 4.3) | 27.8 (18.3, 39.8) |
Otherb | 7.1 (5.7, 8.9) | 4.6 (4.1, 5.1) | 0.8 (0.3, 2.5) | 2.0 (1.0, 4.1) | 1.8 (1.3, 2.4) | 0.2 (0.1, 0.7) | 0.1 (<0.1, 0.4) | <0.1 (<0.1, 0.3) |
Registered with a National Drug Regulatory Authority | 36.4 (32.8, 40.3) | 53.1 (52.0, 54.1) | 41.6 (33.5, 50.3) | 60.5 (57.6, 63.4) | 64.7 (63.4, 66.1) | n/a | 89.6 (87.8, 91.2) | 79.5 (70.9, 86.1) |